EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Key Pharmacokinetic Parameters of 74 Pediatric Anticancer Drugs Providing Assistance in Preclinical Studies

Nora Jamaladdin, Romain Sigaud iD, Daniela Kocher, Anna S Kolodziejczak, Leo F Nonnenbroich, Jonas Ecker, Diren Usta, Julia Benzel, Heike Peterziel, Kristian W Pajtler, Cornelis M van Tilburg iD, Ina Oehme iD und 2 weitere

Clinical Pharmacology & Therapeutics · 2023-10 · 114 (4) · 904-913

DOI: 10.1002/cpt.3002 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 25.07.2023. Verfasst von Nora Jamaladdin und 13 weiteren Autor:innen. Beteiligte Einrichtung: Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany. Hauptthemen laut MEDLINE: Antineoplastic Agents, Carcinoma. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Novel drug treatments for pediatric patients with cancer are urgently needed. Success of drug development in pediatric oncology has been promising, but many drugs still fail in translation from preclinical to clinical phases. To increase the translational potential, several improvements have been implemented, including the use of clinically achievable concentrations in the drug testing phase. Although pharmacokinetic (PK) parameters of numerous investigated drugs are published, a comprehensive PK overview of the most common drugs in pediatric oncology could guide preclinical trial design and improve the translatability into clinical trials. A review of the literature was conducted for PK parameters of 74 anticancer drugs, from the drug sensitivity profiling library of the INdividualized Therapy FOr Relapsed Malignancies in Childhood (INFORM) registry. PK data in the pediatric population were reported and complemented by adult parameters when no pediatric data were available. In addition, blood–brain barrier (BBB)‐penetration assessment of drugs was provided by using the BBB score. Maximum plasma concentration was available for 73 (97%), area under the plasma concentration‐time curve for 69 (92%), plasma protein binding for 66 (88%), plasma half‐life for 57 (76%), time to maximum concentration for 54 (72%), clearance for 52 (69%), volume of distribution for 37 (49%), lowest plasma concentration reached by the drug before the next dose administration for 21 (28%), and steady‐state concentration for 4 (5%) of drugs. Pediatric PK data were available for 48 (65%) drugs. We provide a comprehensive review of PK data for 74 drugs studied in pediatric oncology. This data set can serve as a reference to design experiments more closely mimicking drug PK conditions in patients, and may thereby increase the probability of successful clinical translation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsCarcinomaAdultHumansChildNeoplasm Recurrence, LocalResearchMedical Oncology

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
  • Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center (DKFZ) and German Consortium for Translational Cancer Research (DKTK), Heidelberg, Germany.
  • Faculty of Biosciences, Heidelberg University, Heidelberg, Germany.
  • Faculty of Medicine, Heidelberg University, Heidelberg, Germany.
  • KiTZ Clinical Trial Unit (ZIPO), Department of Pediatric Hematology and Oncology, Heidelberg University Hospital, Heidelberg, Germany.
  • National Center for Tumor Diseases (NCT), Heidelberg, Germany.

ORCID-Profile: Romain Sigaud, Cornelis M van Tilburg, Ina Oehme, Till Milde

Zitieren

APA

Jamaladdin, N., Sigaud, R., Kocher, D., Kolodziejczak, A. S., Nonnenbroich, L. F., Ecker, J., Usta, D., Benzel, J., Peterziel, H., Pajtler, K. W., van Tilburg, C. M., Oehme, I., Witt, O., & Milde, T. (2023). Key Pharmacokinetic Parameters of 74 Pediatric Anticancer Drugs Providing Assistance in Preclinical Studies. Clinical Pharmacology & Therapeutics, 114(4), 904-913. https://doi.org/10.1002/cpt.3002

Vancouver

Jamaladdin N, Sigaud R, Kocher D, Kolodziejczak AS, Nonnenbroich LF, Ecker J, et al. Key Pharmacokinetic Parameters of 74 Pediatric Anticancer Drugs Providing Assistance in Preclinical Studies. Clinical Pharmacology & Therapeutics. 2023;114(4):904-913. doi:10.1002/cpt.3002

BibTeX
@article{Jamaladdin2023,
  author = {Jamaladdin, Nora and Sigaud, Romain and Kocher, Daniela and Kolodziejczak, Anna S and Nonnenbroich, Leo F and Ecker, Jonas and Usta, Diren and Benzel, Julia and Peterziel, Heike and Pajtler, Kristian W and van Tilburg, Cornelis M and Oehme, Ina and Witt, Olaf and Milde, Till},
  title = {Key Pharmacokinetic Parameters of 74 Pediatric Anticancer Drugs Providing Assistance in Preclinical Studies},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2023},
  volume = {114},
  number = {4},
  pages = {904--913},
  doi = {10.1002/cpt.3002}
}
Kostenlos starten →